Xeris Biopharma Holdings Inc (NASDAQ: XERS) on Tuesday, soared 1.24% from the previous trading day, before settling in for the closing price of $3.22. Within the past 52 weeks, XERS’s price has moved between $1.46 and $3.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 195.35%. The company achieved an average annual earnings per share of 14.81%. With a float of $136.46 million, this company’s outstanding shares have now reached $138.13 million.
Considering the fact that the conglomerate employs 377 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 79.24%, operating margin of -20.5%, and the pretax margin is -32.57%.
Xeris Biopharma Holdings Inc (XERS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Xeris Biopharma Holdings Inc is 8.42%, while institutional ownership is 38.20%. The most recent insider transaction that took place on Aug 12 ’24, was worth 10,147. In this transaction Director of this company bought 4,515 shares at a rate of $2.25, taking the stock ownership to the 25,200 shares. Before that another transaction happened on Aug 09 ’24, when Company’s Director bought 4,285 for $2.37, making the entire transaction worth $10,134. This insider now owns 20,685 shares in total.
Xeris Biopharma Holdings Inc (XERS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 14.81% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Xeris Biopharma Holdings Inc (XERS) is currently performing well based on its current performance indicators. A quick ratio of 1.69 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.42, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.23 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Compared to the last year’s volume of 1.69 million, its volume of 1.21 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 60.28%. Additionally, its Average True Range was 0.14.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 90.44%, which indicates a significant increase from 69.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 22.08% in the past 14 days, which was lower than the 49.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.93, while its 200-day Moving Average is $2.47. Nevertheless, the first resistance level for the watch stands at $3.33 in the near term. At $3.39, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.51. If the price goes on to break the first support level at $3.15, it is likely to go to the next support level at $3.03. Now, if the price goes above the second support level, the third support stands at $2.97.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
Market capitalization of the company is 485.74 million based on 148,999K outstanding shares. Right now, sales total 163,910 K and income totals -62,260 K. The company made 48,070 K in profit during its latest quarter, and -15,010 K in sales during its previous quarter.
